Canaccord Genuity Downgrades Synageva BioPharma (GEVA) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases
May 6, 2015 6:39 AM EDT-- Expands Alexions metabolic franchise with the addition of Kanuma (sebelipase alfa) for LAL Deficiency (LAL-D) --
-- Launches of Kanuma and Alexions Strensiq (asfotase alfa) expected in 2015 --
-- Creates the most robust rare disease pipeline in biotech; adds SBC-103 for MPS IIIB to clinical development programs --
-- Combined pipeline to have eight highly innovative product candidates in the clinic for eleven indications --
-- Preclinical pipeline to have more than 30 diverse programs across a range of therapeutic... More
